Zhifeilongkoma

Anhui Zhifei Longkoma Biopharmaceutical Co., Ltd. is a leading Chinese biotechnology company and a core subsidiary of Chongqing Zhifei Biological Products. The company specializes in the research, development, and large-scale manufacturing of vaccines and biological products, with a primary focus on infectious diseases. It achieved significant global prominence for developing Zifivax (ZF2001), a recombinant protein subunit vaccine for COVID-19, and the recombinant Mycobacterium tuberculosis fusion protein (EC) diagnostic kit. Zhifei Longkoma operates state-of-the-art GMP-certified facilities and maintains a robust clinical pipeline targeting rabies, influenza, and pneumonia. The company is a key player in China's public health infrastructure and continues to expand its footprint in international markets through strategic collaborations.